Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03312543 · ClinicalTrials.gov registry record · NA

Evaluation of the Efficacy and Tolerance of a Light Therapy Mask on Mild to Moderate Brown Spots and Moderate to Severe Facial Wrinkles

A NA study, sponsored by Johnson & Johnson Consumer Inc. (J&JCI).

Completed
Registry status
NA
Development phase
124
Enrollment target

NCT03312543: Completed NA study, sponsored by Johnson & Johnson Consumer Inc. (J&JCI).

NCT03312543 is a NA study that has completed, run by Johnson & Johnson Consumer Inc. (J&JCI). The registered enrollment target is 124 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03312543, a NA study, has completed, sponsored by Johnson & Johnson Consumer Inc. (J&JCI).

COMPLETED
Registry status
NA
Development phase
124 participants
Enrollment target

Study Summary

This research study will test how well a light therapy mask works for women with mild to moderate hyperpigmentation (brown spots) and moderate to severe facial wrinkles, as compared to a "sham" or inactive investigational light therapy mask. The study will also test if the light therapy mask causes any irritation. For the first 12 weeks of the study, participants will use the assigned mask, along with a provided cleanser and sunscreen. For the second 12 weeks of the study, participants will use just the cleanser and sunscreen.

Primary Outcome

3 Expert Graders evaluated global wrinkling on a 1-9 scale, where 1 = mildest wrinkles to 9 = most severe wrinkles. The 3 Expert Grader scores were averaged for Baseline and for Week 12. Change from baseline was calculated as Baseline mean minus Week 12 mean so a positive score indicates improvement.

Interventions

  • DEVICE Active Mask
  • DEVICE Sham Mask

Trial Details

FieldValue
Enrollment Target 124 participants
Start Date 2017-10-09
Est. Completion 2018-04-06
Phase NA

What the finished NCT03312543 record still lists

NCT03312543 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).

The record links to 0 conditions, and to 2 interventions - of which Active Mask is the first listed.

NCT03312543 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03312543 about?

NCT03312543 is a clinical study titled "Evaluation of the Efficacy and Tolerance of a Light Therapy Mask on Mild to Moderate Brown Spots and Moderate to Severe Facial Wrinkles". This research study will test how well a light therapy mask works for women with mild to moderate hyperpigmentation (brown spots) and moderate to severe facial wrinkles, as compared to a "sham" or inactive investigational light therapy mask. The study will also test if the light therapy mask causes ...

What is the current status of trial NCT03312543?

This trial is currently completed. It is a NA study. The enrollment target is 124 participants. The study started on 2017-10-09. Estimated completion is 2018-04-06.

What interventions are being tested in trial NCT03312543?

The interventions under investigation include: Active Mask (DEVICE), Sham Mask (DEVICE).

Who is sponsoring clinical trial NCT03312543?

This trial is sponsored by Johnson & Johnson Consumer Inc. (J&JCI), which has 40 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03312543's enrollment target sits among peer trials

124 758th of 2000 higher than 1,239 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02523014 · 124 participants · Phase 2

    Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

  • NCT02670707 · 124 participants · Phase 3

    Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)

  • NCT02830724 · 124 participants · Phase 1

    Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

  • NCT04748809 · 124 participants · NA

    Effect of Anti-inflammatory Diet in Rheumatoid Arthritis

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03312543, the US trial registry maintained by the National Library of Medicine. NCT03312543 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.